- Home
- IGC
IGC
IGC Pharma Inc.
as 11-21-2024 4:00pm EST
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | POTOMAC |
| Market Cap: | 26.9M | IPO Year: | N/A |
| Target Price: | $3.63 | AVG Volume (30 days): | 222.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.25 - $0.91 | Next Earning Date: | 11-12-2024 |
| Revenue: | $1,183,000 | Revenue Growth: | -11.91% |
| Revenue Growth (this year): | -15.09% | Revenue Growth (next year): | 13.57% |
Stock Insider Trading Activity of IGC Pharma Inc. (IGC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Moran James P | IGC | Director | Sep 25 '24 | Buy | $0.34 | 588,235 | $199,999.90 | 942,402 |
Latest IGC Pharma Inc. News
IGC Breaking Stock News: Dive into IGC Ticker-Specific Updates for Smart Investing
ACCESSWIRE
7 days ago
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline
ACCESSWIRE
15 days ago
IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies
ACCESSWIRE
a month ago
IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1
ACCESSWIRE
2 months ago
IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge
Business Wire
2 months ago
IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment
Business Wire
3 months ago
IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease
Business Wire
3 months ago
IGC Announces Results of its 2024 Annual Stockholders Meeting
Business Wire
3 months ago
IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease
Compare IGC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IGC IGC Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.